Literature DB >> 23002345

Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.

Jung Il Lee1, Jin-Woo Lee, Joon Mee Kim, Ja Kyung Kim, Hyun Jung Chung, Young Soo Kim.   

Abstract

AIM: To investigate whether expressing biliary phenotype predicted poor outcome after the surgical treatment in primary liver cancers.
METHODS: Out of 204 patients that underwent liver resection due to hepatocellular carcinoma (HCC), liver specimens of 70 patients with HCC were evaluated for biliary components by cytokeratin (CK) 19 immunostain (CK19⁻ HCC and CK19⁺ HCC). CK19 positivity was defined as membranous and/or cytoplasmic expression in ≥ 5% of tumor cells with moderate or strong intensity. Patients with other primary liver cancers, such as combined HCC and cholangiocarcinoma (cHCC-CC), intrahepatic cholangiocarcinoma (ICC) who received curative liver resection, were also included in the study. Clinical characteristics of CK19⁻ HCC and CK19⁺ HCC patients, including survival outcome after curative liver resection, were compared with that of cHCC-CC and ICC patients.
RESULTS: The overall survival (OS) rate of CK19⁻ HCC (n = 49) after the curative surgical treatment was 90.7%, and 80.4% at 1 and 5 years after the resection. OS rate of CK19⁺ HCC (n = 21) was 74.3%, 28.9% and OS rate of cHCC-CC (n = 22) was 66.7%, 32.2% at 1 and 5 years after the surgery. For ICC (n = 19), 1 and 5-year-OS rate was 50.2% and 14.3% after the curative resection. The OS rates of CK19⁺ HCC and cHCC-CC were significantly lower than that of CK19⁻ HCC, but higher than the OS rate of ICC (P = 0.000). There was no statistically significant difference in OS rate between CK19⁺ HCC and cHCC-CC. The disease free survival (DFS) rate of CK19⁻ HCC was 72.0% and 54.5% at 1 and 3 years after the surgical treatment. DFS rate of CK19⁺ HCC was 53.3%, 34.3% and DFS rate of cHCC-CC was 51.5%, 39.2% at 1 and 3 years after the resection. For ICC, 1 and 3-year-DFS rate was 28.0% and 14.0% after the curative resection. DFS rate of CK19⁻ HCC was significantly higher than that of ICC (P = 0.017), but marginally higher than DFS rate of either CK19⁺ HCC or cHCC-CC (P = 0.097, P = 0.089, respectively). Predictors of outcome after the surgery of primary liver cancer were pathology of the resected mass, existence of microvascular invasion and accompanying satellite nodule.
CONCLUSION: Primary liver cancers with biliary components tended to show poorer surgical outcome. This suggested that immuno-phenotype of liver cancers was as important as their morphological classification.

Entities:  

Keywords:  Cytokeratin 19; Hepatectomy; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Liver cancers

Mesh:

Substances:

Year:  2012        PMID: 23002345      PMCID: PMC3442214          DOI: 10.3748/wjg.v18.i34.4751

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

2.  Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.

Authors:  Mina Komuta; Bart Spee; Sara Vander Borght; Rita De Vos; Chris Verslype; Raymond Aerts; Hirohisa Yano; Tetsuya Suzuki; Masanori Matsuda; Hideki Fujii; Valeer J Desmet; Masamichi Kojiro; Tania Roskams
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

3.  Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor.

Authors:  Shun-Ichi Ariizumi; Yoshihito Kotera; Satoshi Katagiri; Masayuki Nakano; Masakazu Yamamoto
Journal:  Ann Surg Oncol       Date:  2011-11-24       Impact factor: 5.344

4.  Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Jeong-Hoon Lee; Goh Eun Chung; Su Jong Yu; Sang Youn Hwang; Joon Suk Kim; Hwi Young Kim; Jung-Hwan Yoon; Hyo-Suk Lee; Nam-Joon Yi; Kyung-Suk Suh; Kuhn Uk Lee; Ja-June Jang; Yoon Jun Kim
Journal:  J Clin Gastroenterol       Date:  2011-01       Impact factor: 3.062

5.  Histopathological classification of hepatocellular carcinoma.

Authors:  Massimo Roncalli; Young Nyun Park; Luca Di Tommaso
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

6.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

7.  Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma.

Authors:  Xiong Cai; Jian Zhai; David E Kaplan; Yijun Zhang; Lining Zhou; Xutao Chen; Guangyang Qian; Qiudong Zhao; Yonghai Li; Lu Gao; Wenming Cong; Minghua Zhu; Zhenlin Yan; Lehua Shi; Dong Wu; Lixin Wei; Feng Shen; Mengchao Wu
Journal:  Hepatology       Date:  2012-06-25       Impact factor: 17.425

8.  Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior.

Authors:  Xin-Yuan Lu; Tao Xi; Wan-Yee Lau; Hui Dong; Zhen Zhu; Feng Shen; Meng-Chao Wu; Wen-Ming Cong
Journal:  Ann Surg Oncol       Date:  2011-02-10       Impact factor: 5.344

9.  Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.

Authors:  Hiroto Katoh; Hidenori Ojima; Akiko Kokubu; Shigeru Saito; Tadashi Kondo; Tomoo Kosuge; Fumie Hosoda; Issei Imoto; Johji Inazawa; Setsuo Hirohashi; Tatsuhiro Shibata
Journal:  Gastroenterology       Date:  2007-11       Impact factor: 22.682

10.  Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma: a single center study in Korea.

Authors:  Hana Park; Ki Hong Choi; Sae-Byeol Choi; Jong Won Choi; Do Young Kim; Sang Hoon Ahn; Kyung Sik Kim; Jin Sub Choi; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

View more
  26 in total

1.  Low expression of GNAI3 predicts poor prognosis in patients with HCC.

Authors:  Guodong Chen; Xiaoyan Li; Gengsheng He; Zijian Yu; Jiaxing Luo; Jun He; Zonghai Huang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development.

Authors:  Violeta Zúñiga-García; María de Guadalupe Chávez-López; Valeria Quintanar-Jurado; Nayeli Belem Gabiño-López; Elisabeth Hernández-Gallegos; Juan Soriano-Rosas; Julio Isael Pérez-Carreón; Javier Camacho
Journal:  Dig Dis Sci       Date:  2015-04-05       Impact factor: 3.199

3.  The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia.

Authors:  Kenneth J Salleng; Frank L Revetta; Natasha G Deane; M Kay Washington
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

4.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

5.  Hepatocyte Wnts Are Dispensable During Diethylnitrosamine and Carbon Tetrachloride-Induced Injury and Hepatocellular Cancer.

Authors:  Morgan Preziosi; Minakshi Poddar; Sucha Singh; Satdarshan P Monga
Journal:  Gene Expr       Date:  2018-03-08

6.  Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype.

Authors:  Priscila B de Campos; Claudia P Oliveira; José T Stefano; Sebastião N Martins-Filho; Aline L Chagas; Paulo Herman; Luiz C D'Albuquerque; Mário R Alvares-da-Silva; Adhemar Longatto-Filho; Flair J Carrilho; Venancio A F Alves
Journal:  Histol Histopathol       Date:  2019-12-20       Impact factor: 2.303

7.  Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy.

Authors:  Shang-Dong Qin; Jie Zhang; Ya-Peng Qi; Jian-Hong Zhong; Bang-De Xiang
Journal:  World J Surg Oncol       Date:  2022-06-21       Impact factor: 3.253

8.  Expression of bile duct transcription factor HNF1β predicts early tumor recurrence and is a stage-independent prognostic factor in hepatocellular carcinoma.

Authors:  Ray-Hwang Yuan; Hong-Shiee Lai; Hey-Chi Hsu; Po-Lin Lai; Yung-Ming Jeng
Journal:  J Gastrointest Surg       Date:  2014-07-23       Impact factor: 3.452

Review 9.  Prognostic factors for hepatocellular carcinoma recurrence.

Authors:  Antonio Colecchia; Ramona Schiumerini; Alessandro Cucchetti; Matteo Cescon; Martina Taddia; Giovanni Marasco; Davide Festi
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 10.  Recent advances in the surgical management of hepatocellular carcinoma.

Authors:  Georgios K Glantzounis; Anastasia Karampa; Dimitra V Peristeri; George Pappas-Gogos; Kostas Tepelenis; Petros Tzimas; Dimitrios J Cyrochristos
Journal:  Ann Gastroenterol       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.